Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Crinetics Pharmaceuticals Inc.
The First Affiliated Hospital of Xiamen University
Boston Scientific Corporation
Memorial Sloan Kettering Cancer Center
University of Florida
Intergroupe Francophone de Cancerologie Thoracique
SystImmune Inc.
IDEAYA Biosciences
Hospices Civils de Lyon
Molecular Partners AG
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Technische Universität Dresden
Eastern Cooperative Oncology Group
Ohio State University Comprehensive Cancer Center
University of Iowa
University of Miami
M.D. Anderson Cancer Center
Tanabe Pharma America, Inc.
UNICANCER
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Wren Laboratories LLC
National Institutes of Health Clinical Center (CC)
AbbVie
M.D. Anderson Cancer Center
Centre Hospitalier Universitaire Dijon
Latin American Cooperative Oncology Group
Phanes Therapeutics
Vyriad, Inc.
Travera Inc
Asan Medical Center
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Hospices Civils de Lyon
Fudan University
Case Comprehensive Cancer Center
Radio Isotope Therapy of America
Fox Chase Cancer Center
GERCOR - Multidisciplinary Oncology Cooperative Group
National Institutes of Health Clinical Center (CC)
Turning Point Therapeutics, Inc.
Hoffmann-La Roche
M.D. Anderson Cancer Center
Hansoh BioMedical R&D Company
National Institutes of Health Clinical Center (CC)
University of Roma La Sapienza
Intergroupe Francophone de Cancerologie Thoracique
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS